LONDON (Alliance News) - Verona Pharma PLC said Monday the first cohort of volunteers have been dosed with its new nebulised formulation of its RPL554 compound as part of a Phase I/II clinical trial profiling the new formulation.
Verona is initially developing the compound as a treatment for acute exacerbations in patients with chronic obstructive pulmonary disease. Up to 120 subjects are planned to be recruited for the study, with results expected to be available in the second half of 2015.
The study's primary objective is to confirm the safety, tolerability and bronchodilation of the product.
"We believe that this new proprietary formulation for nebulised RPL554 will allow us to develop optimally and commercialise this unique drug as an effective treatment for acute exacerbations in chronic obstructive pulmonary disease," said Chief Executive Officer Jans-Anders Karlsson in a statement.
Shares in Verona Pharma are trading up 3.3% at 1.24 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.